Learn About Our Current Clinical Trials - ECHO Associates

Learn About Our Current Clinical Trials

Clinical trials offer patients access to promising new therapies while helping advance cancer research and future treatment options. Participation is voluntary, and eligibility requirements apply to each study. Below are ECHO’s current trials. Please check back regularly for updates. For information about any of the clinical trials listed, please contact: Dr. Spiro Curis scuris@echoct.com or (860) 886-8362, x251.

Lung

V940-009

For Patients with Non-Small Cell Lung Cancer (NSCLC) After Surgery and Prior Treatment

This clinical trial is studying whether adding an investigational personalized cancer vaccine called V940 to the immunotherapy drug pembrolizumab may help reduce the risk of cancer returning after treatment.

Patients in this study:

  • Have non-small cell lung cancer (NSCLC)
  • Have already received treatment before surgery (called neoadjuvant therapy)
  • May still have some remaining cancer cells after surgery

Researchers are evaluating whether this combination can help the immune system better recognize and fight any remaining cancer cells.

Treatment being studied:

  • Pembrolizumab (an FDA-approved immunotherapy)
  • V940 (an investigational personalized mRNA cancer vaccine)

Mirati 849-007

For Patients with KRAS G12C Positive Non-Small Cell Lung Cancer

This study is evaluating a combination of targeted therapy and immunotherapy as a first treatment for patients with advanced non-small cell lung cancer (NSCLC) that contains a specific genetic mutation called KRAS G12C.

Patients in this study:

  • Have advanced or metastatic NSCLC
  • Have a KRAS G12C mutation
  • Have not yet received treatment for advanced disease

Researchers are studying whether combining adagrasib, a targeted therapy, with pembrolizumab, an immunotherapy, may improve outcomes for patients with this specific type of lung cancer.

Treatment being studied:

  • Adagrasib (targeted therapy)
  • Pembrolizumab (immunotherapy)

OSE210C302

For Patients with Advanced Non-Small Cell Lung Cancer After Prior Immunotherapy

This clinical trial is studying an investigational immunotherapy called OSE2101 compared to standard chemotherapy (docetaxel) in patients whose cancer has progressed after treatment with immune checkpoint inhibitors.

Patients in this study:

  • Have advanced NSCLC
  • Previously received immunotherapy
  • Experienced cancer progression after treatment

Researchers hope to learn whether OSE2101 can help the immune system better fight lung cancer while potentially offering an alternative to standard chemotherapy.

Treatments being studied:

  • OSE2101 (investigational cancer vaccine/immunotherapy)
  • Docetaxel (standard chemotherapy)

Amgen 178

For Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

This study is evaluating whether adding a new investigational immunotherapy called tarlatamab to standard first-line treatment may improve outcomes for patients with extensive-stage small cell lung cancer.

Patients in this study:

  • Have extensive-stage small cell lung cancer (ES-SCLC)
  • Have not yet received treatment for extensive-stage disease

Researchers are studying the safety and effectiveness of combining tarlatamab with chemotherapy and durvalumab, a standard immunotherapy treatment.

Treatments being studied:

  • Tarlatamab (investigational immunotherapy)
  • Chemotherapy
  • Durvalumab (immunotherapy)

GI/Colorectal

SMT112-3005

For Patients with Metastatic Colorectal Cancer

This clinical trial is studying whether an investigational immunotherapy drug called ivonescimab combined with standard chemotherapy may work better than the current standard treatment for patients with metastatic colorectal cancer.

Patients in this study:

  • Have metastatic colorectal cancer
  • Are receiving first-line treatment for advanced disease

Researchers are comparing two treatment approaches to evaluate safety and effectiveness in controlling cancer growth.

Treatments being studied:

  • Ivonescimab + FOLFOX chemotherapy
  • Bevacizumab + FOLFOX chemotherapy (standard treatment comparison)

Hematologic Clinical Trials

BGB-11417-303

For Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

This study is evaluating a new targeted therapy combination for patients whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has returned after prior treatment.

Patients in this study:

  • Have relapsed or recurrent CLL/SLL
  • Previously received treatment for their disease

Researchers are studying whether the investigational drug sonrotoclax combined with anti-CD20 therapy may be as effective or more effective than current standard treatment options.

Treatments being studied:

  • Sonrotoclax + anti-CD20 therapy
  • Venetoclax + rituximab (standard treatment comparison)

MK-1026-011

For Patients Newly Diagnosed with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

This clinical trial is evaluating an investigational targeted therapy called nemtabrutinib compared to currently approved targeted therapies for patients newly diagnosed with CLL or SLL.

Patients in this study:

  • Have newly diagnosed CLL/SLL
  • Have not yet started treatment

Researchers are studying whether nemtabrutinib may provide another effective treatment option for patients with these blood cancers.

Treatments being studied:

  • Nemtabrutinib
  • Ibrutinib or acalabrutinib (approved targeted therapies)

Solid Tumors

RMC-APEX-103

For Patients with Advanced Solid Tumors with RAS Mutations

This “basket” clinical trial is studying an investigational targeted therapy for patients whose cancers contain specific RAS gene mutations.

Patients in this study:

  • Have advanced solid tumors
  • Have cancers with RAS mutations

Because RAS mutations can occur in many different cancer types, this study includes patients with a variety of solid tumors sharing this genetic change.

Researchers are evaluating the safety and effectiveness of a RAS(ON) inhibitor used alone or in combination with other treatments.

Treatment being studied:

  • Investigational RAS(ON) inhibitor therapy

Genitourinary Clinical Trials

Pfizer C6461006

For Patients With Metastatic Urothelial Cancer

This study is evaluating an investigational treatment for patients with metastatic urothelial carcinoma, the most common type of bladder cancer.

Patients in this study:

  • Have metastatic urothelial carcinoma

Researchers are studying whether PF-08634404, alone or combined with enfortumab vedotin, may help treat advanced bladder cancer.

Treatments being studied:

  • PF-08634404
  • PF-08634404 + enfortumab vedotin

Supportive Care & Research Studies

Tempus Gemini

NSCLC Monitoring Study

This observational study uses advanced molecular testing to help monitor non-small cell lung cancer (NSCLC).

Patients in this study:

  • Have NSCLC

Researchers collect and analyze blood and tumor information to better understand cancer behavior and treatment response over time.

Tempus Aries

Tissue Collection and Genomic Research Registry

This research registry collects tissue samples and genomic information to support future cancer research and precision medicine efforts.

Patients who participate:

  • Contribute tissue and health information for research purposes

The goal is to help researchers better understand cancer biology and develop future personalized treatments.

CLIN-53

Neuropathy Prevention Study

This supportive care study is evaluating whether a compression device may help prevent neuropathy, a common side effect of certain chemotherapy treatments.

Patients in this study:

  • Are receiving treatments that may cause neuropathy

Researchers are studying ways to reduce numbness, tingling, pain, and nerve-related side effects during cancer treatment.

Natera MRD

Minimal Residual Disease (MRD) Monitoring

This diagnostic study uses a blood test called circulating tumor DNA (ctDNA) testing to monitor for minimal residual disease (MRD), which refers to very small amounts of cancer that may remain after treatment.

Patients in this study:

  • Undergo blood-based cancer monitoring

Researchers and physicians use this information to better track treatment response and possible recurrence.

Coming Soon / Pre-Screening Studies

DREAMM-15

For Patients with Relapsed or Refractory Multiple Myeloma

This upcoming clinical trial is evaluating combinations that include belantamab mafodotin for patients whose multiple myeloma has returned or no longer responds to treatment.

Patients in this study:

  • Have relapsed or refractory multiple myeloma

Researchers are studying new combination approaches to improve outcomes for patients with advanced multiple myeloma.

Treatment being studied:

  • Belantamab mafodotin-based combinations

Interested in Learning More?

Speak with your oncology care team to learn whether a clinical trial may be appropriate for you or your loved one. For information about the above clinical trials, please contact: Dr. Spiro Curis scuris@echoct.com or (860) 886-8362, x251.